Genmab — August 2020

[Sukkeralf]

Medwatch om Tepezza

[Sukkeralf]

Aflagt Genmab-middel sælger stort – milliarder kan være på vej i royalties

Det tidligere Genmab-middel Tepezza sælger langt bedre, end hvad den nuværende ejer Horizon Therapeutics turde håbe på. Da Genmab har ret til royalties, kan der være milliarder på vej til det danske biotekfirma.

(medwatch.dk)

[transalp]

Go morgen..

[Mogan]

God morgen

[Helge_LarsenPI-redaktør]

Trump igen igen: https://www.proinvestor.com/investornyt/664577/trump-fortsaetter-pres-pa-europaeiske-healthcarenu-med-kob-usa-medicin

[Solsen]

Nu har han hamstret covid-19 medicin og omdirigeret fly med mundbind - manden er forhåbentlig ude næste år.

[Bella1]

I så fald venter det totale kaos...

[Mcjean]

Hmmm synes essensen i denne historie og de tiltag han laver virker yderst fornuftige, overskriften kan måske forvirre lidt og virker faktisk direkte latterlig og misvisende.

[Bella1]

• når overskrifter forfattes af fjenden...

[Solsen]

Det er vi så ikke enige i

[Mcjean]

Virker nærmest som ren manipulation.......og så sætter man Novo's flag ind i artiklen, det burde politianmeldes......har de shortet NOVO, dette har intet med NOVO at gøre.

[Sukkeralf]

Janssens first DuoBody that did not make it - old stuff for hardcore fans:

[Sukkeralf]

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A - PubMed

Tumor necrosis factor (TNF) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA). JNJ-61178104 is a novel human anti-TNF and anti-IL-17A monovalent, bispecific antibody that …

PubMed (pubmed.ncbi.nlm.nih.gov)

[Sukkeralf]

JNJ-61178104 was shown to engage its targets, TNF and IL-17A, in systemic circulation measured as drug/target complex formation in normal cynomolgus monkeys (cyno). Surprisingly, quantitative target engagement assessment suggested lower apparent in vivo target-binding affinities for JNJ-61178104 compared to its bivalent parental antibodies, despite their similar in vitro target-binding affinities.

[Sukkeralf]

The target engagement profiles of JNJ-61178104 in humans were in general agreement with the predicted profiles based on cyno data, suggesting similar differences in the apparent in vivo target-binding affinities. These findings show that in vivo target engagement of monovalent bispecific antibody does not necessarily recapitulate that of the molar-equivalent dose of its bivalent parental antibody

[Sukkeralf]

Our results also offer valuable insights into the understanding of the pharmacokinetics/pharmacodynamics and target engagement of other bispecific biologics against dimeric and/or trimeric soluble targets in vivo.

[E_L]

it is a shame as it is the only JNJ non-cancer duobody as far as i am aware of? i am not sure how much 'valuable insights' they gained from this, besides confirming how hard it is lol

[E_L]

but , who knows, maybe in 20 years or so they will find it actually works for Graves disease or something

[E_L]

actually only just noticed that clicking on the link behing DOI will give the full article,

[Sukkeralf]

I dont spend time reading that stuff - do you ?